Literature DB >> 29270980

Eltrombopag, low-dose rituximab, and dexamethasone combination as frontline treatment of newly diagnosed immune thrombocytopaenia.

David Gómez-Almaguer1, Perla R Colunga-Pedraza1, Andrés Gómez-De León1, César H Gutiérrez-Aguirre1, Olga G Cantú-Rodríguez1, José C Jaime-Pérez1.   

Abstract

Entities:  

Keywords:  dexamethasone; eltrombopag; immune thrombocytopenia; rituximab

Mesh:

Substances:

Year:  2017        PMID: 29270980     DOI: 10.1111/bjh.15070

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  7 in total

1.  Immune thrombocytopenia associated with Hashimoto thyroiditis in a pediatric patient: A case report.

Authors:  Zhiqing Tian; Hu Gao; Dongqiong Xiao; Xihong Li
Journal:  Medicine (Baltimore)       Date:  2021-06-04       Impact factor: 1.817

2.  Treatment of autoimmune hemolytic anemia: real world data from a reference center in Mexico.

Authors:  José Carlos Jaime-Pérez; Patrizia Aguilar-Calderón; Lorena Salazar-Cavazos; Andrés Gómez-De León; David Gómez-Almaguer
Journal:  Blood Res       Date:  2019-06-25

Review 3.  Rituximab in the treatment of immune thrombocytopenia: what is the role of this agent in 2019?

Authors:  Elisa Lucchini; Francesco Zaja; James Bussel
Journal:  Haematologica       Date:  2019-05-24       Impact factor: 9.941

4.  First-line Therapy for Immune Thrombocytopenia: Time for Change.

Authors:  Roger E G Schutgens
Journal:  Hemasphere       Date:  2022-09-22

Review 5.  Understanding Immune Thrombocytopenia: Looking Out of the Box.

Authors:  Alexandra Schifferli; Franco Cavalli; Bertrand Godeau; Howard A Liebman; Mike Recher; Paul Imbach; Thomas Kühne
Journal:  Front Med (Lausanne)       Date:  2021-06-24

Review 6.  Evans syndrome: clinical perspectives, biological insights and treatment modalities.

Authors:  José Carlos Jaime-Pérez; Patrizia Elva Aguilar-Calderón; Lorena Salazar-Cavazos; David Gómez-Almaguer
Journal:  J Blood Med       Date:  2018-10-10

7.  Could Antinuclear Antibody Positivity Be a Factor Affecting Treatment Response in Immune Thrombocytopenia Patients on Eltrombopag?

Authors:  Mehmet Baysal; Volkan Baş; Elif Ümit; Hakkı Onur Kırkızlar; Ahmet Muzaffer Demir
Journal:  Turk J Haematol       Date:  2021-06-24       Impact factor: 1.831

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.